• PDF: Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)

Triple Analysis: Breast Cancer, Lung Cancer and Prostate Cancer

  • Publication Date:September 2012
  • Publisher:Bioseeker
  • Product Type: Report
  • Pages:4571

Triple Analysis: Breast Cancer, Lung Cancer and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer

The breast cancer drug report part comprises defined and up to date development strategies for 470 drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer drug development.

This part is based on the following publication:

Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Lung Cancer

The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.

This part is based on the following publication:

Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part III: Prostate Cancer

The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.

This part is based on the following publication:

Competitive Handbook towards Personalized Medicine in Prostate Cancer

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

  • Key Topics Covered:
  • Part I: Breast Cancer
    • 5.1 The Scope of this Report 32
    • 6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (234 Drug Targets) 36-522
    • 7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development (223 Drug Target Strategies and 470 Drugs) 523-797
    • 8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Compound Strategies) 798-850
    • 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator (247 Investigators and 470 Drugs) 851-1723
    • 10 Disclaimer 1724
  • Figures: Includes 8 Figures
  • Tables: Includes 309 Tables
  • Total Number of Pages: 1,755
  • Part II: Lung Cancer
    • 5.1 The Scope of this Report 31
    • 6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
    • 7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
    • 8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
    • 9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
    • 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
    • 11 Disclaimer 1300
    • 12 Drug Index 1301
    • 13 Company Index 1314
  • Figures: Includes 7 Figures
  • Tables: Includes 284 Tables
  • Total Number of Pages: 1323
  • Part III: Prostate Cancer
    • 5.1 The Scope of this Report 31
    • 6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
    • 7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
    • 8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
    • 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
    • 10 Disclaimer 1471
  • Figures: Includes 8 Figures
  • Tables: Includes 283 Tables
  • Total Number of Pages: 1,493
+44 20 8816 8548

Ask a question about Triple Analysis: Breast Cancer, Lung Cancer and Prostate Cancer

Enter the characters you see in the picture below
Captcha